Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.
November 06, 2017 16:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017
November 06, 2017 10:04 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors
September 26, 2017 16:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
September 19, 2017 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
September 12, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir
September 06, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress
August 21, 2017 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
August 09, 2017 17:04 ET
|
Argos Therapeutics Inc.
- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data...
Argos Reports Immunogenicity Results of AGS-004 in HIV Program
July 26, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing
June 22, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...